FDA staffers tee up Gilead's hep C drug sofosbuvir for upbeat panel meeting

Gilead Sciences ($GILD) may be able to break out the champagne soon if the FDA's review of its hepatitis C drug sofosbuvir is any indication. Ahead of Friday's advisory panel meeting, the agency's staff highlighted sofosbuvir's all-oral treatment approach, with faster cures and fewer side effects than older meds. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.